{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FF%2FVI+%28100%2F25%29+mcg",
    "query": {
      "intervention": "FF/VI (100/25) mcg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FF%2FVI+%28100%2F25%29+mcg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T13:36:52.611Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01706328",
      "title": "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/VI 100/25 Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 828,
      "start_date": "2012-10-15",
      "completion_date": "2013-06-17",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 16,
      "location_summary": "Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Woodbury",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01706328"
    },
    {
      "nct_id": "NCT01894386",
      "title": "Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF 400 mcg",
          "type": "DRUG"
        },
        {
          "name": "UMEC 500 mcg",
          "type": "DRUG"
        },
        {
          "name": "UMEC 250 mcg",
          "type": "DRUG"
        },
        {
          "name": "VI 100 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-07-15",
      "completion_date": "2013-09-26",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894386"
    },
    {
      "nct_id": "NCT02105974",
      "title": "Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1621,
      "start_date": "2014-04-07",
      "completion_date": "2015-07-08",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 17,
      "location_summary": "Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Sunset",
          "state": "Louisiana"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02105974"
    },
    {
      "nct_id": "NCT02119286",
      "title": "Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF",
          "type": "DRUG"
        },
        {
          "name": "VI",
          "type": "DRUG"
        },
        {
          "name": "UMEC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 620,
      "start_date": "2013-10",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 14,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02119286"
    },
    {
      "nct_id": "NCT03949842",
      "title": "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone furoate/umeclidinium/vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-27",
      "completion_date": "2022-11-30",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 3,
      "location_summary": "Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Layton",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949842"
    },
    {
      "nct_id": "NCT01323621",
      "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg",
          "type": "DRUG"
        },
        {
          "name": "Double-dummy placebo",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2011-03-18",
      "completion_date": "2012-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-02-15",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 13,
      "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323621"
    },
    {
      "nct_id": "NCT02164539",
      "title": "Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF",
          "type": "DRUG"
        },
        {
          "name": "UMEC",
          "type": "DRUG"
        },
        {
          "name": "VI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2014-07-01",
      "completion_date": "2015-07-18",
      "has_results": true,
      "last_update_posted_date": "2017-10-11",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 14,
      "location_summary": "Newport Beach, California • San Diego, California • Upland, California + 11 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Sunset",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02164539"
    },
    {
      "nct_id": "NCT01453023",
      "title": "Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 26,
      "start_date": "2011-10",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 1,
      "location_summary": "Huntington Beach, California",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453023"
    },
    {
      "nct_id": "NCT02164513",
      "title": "A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "fluticasone furoate (FF)",
          "type": "DRUG"
        },
        {
          "name": "vilanterol (VI)",
          "type": "DRUG"
        },
        {
          "name": "umeclidinium bromide (UMEC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 10355,
      "start_date": "2014-06-30",
      "completion_date": "2017-07-17",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 269,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Florence",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02164513"
    },
    {
      "nct_id": "NCT01323634",
      "title": "Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250mcg/ salmeterol 50mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 519,
      "start_date": "2011-03-18",
      "completion_date": "2011-12-14",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-30T13:36:52.611Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323634"
    }
  ]
}